Comparing IL17 inhibitors and Anti-TNF treatments for Ankylosing Spondylitis
Effect of IL17 Inhibitor in Comparison With Anti-TNF- α on Platelet Count and Its Association With Disease Activity in Patients With Ankylosing Spondylitis
This study is testing whether IL17 inhibitors work better than Anti-TNF treatments for people with Ankylosing Spondylitis who haven't had enough relief from other medications.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 50 (estimated) |
| Ages | 16 Years to 60 Years |
| Sex | All |
| Sponsor | Sohag University Academic / other |
| Locations | 1 site (Sohag) |
| Trial ID | NCT06642207 on ClinicalTrials.gov |
What this trial studies
This observational study aims to compare the effectiveness of IL17 inhibitors with Anti-TNF therapies in patients diagnosed with Ankylosing Spondylitis (AS). It focuses on patients who have experienced inadequate responses to conventional treatments and are currently on biologic disease-modifying antirheumatic drugs (bDMARDs). The study will assess disease activity using patient-reported measures and inflammatory markers to better understand the comparative benefits of these treatment options.
Who should consider this trial
Good fit: Ideal candidates are patients aged 16 to 60 who have been diagnosed with Ankylosing Spondylitis and have not responded adequately to conventional treatments.
Not a fit: Patients with other rheumatologic diseases or those outside the age range of 16 to 60 may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide insights into more effective treatment options for patients with Ankylosing Spondylitis.
How similar studies have performed: While there have been studies on IL17 inhibitors and Anti-TNF therapies, this specific comparative approach in Ankylosing Spondylitis is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients fulfill the Assessment in Spondyloarthritis International Society (ASAS) classification criteria for Axial Spondyloarthritis. * Patients with disease duration more than 6 months. * Patients who failed conventional treatment and on bDMARDs (IL17 or Anti-TNF-α). * Age above 16 years old. * Patient cooperative and can answer questions. * Patients who are able and willing to give written informed consent. Exclusion Criteria: * Other rheumatologic or collagen diseases. * Age below 16 years and above 60 years. * Uncooperative patients. * Patient not able and willing to give written informed consent. * Patient with other causes of platelet dysfunction, count irregularity.
Where this trial is running
Sohag
- Sohag university Hospital — Sohag, Egypt (Recruiting)
Study contacts
- Study coordinator: manar G abd elfattah, resident
- Email: manar_abdelfattah_post@med.sohag.edu.eg
- Phone: 01032330664
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.